Case 1: Transformation of Myelofibrosis to AML
Case 1: The Diagnosis of Myelofibrosis
Case 1: Fedratinib Treatment for Myelofibrosis
Case 1: Ruxolitinib Treatment for Myelofibrosis
Case 1: NCCN Guidelines for Treating Myelofibrosis
Case 1: Risk Stratification Models for Myelofibrosis
Case 1: A 68-Year-Old Woman With Primary Myelofibrosis
Myeloproliferative Neoplasms
Experts in myeloproliferative neoplasms review 4 clinical cases and best practices for patients with, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and blast transformation.
Treating CLL With BTK Inhibition: Next Steps
Resistance to BTK Targeted Therapy in CLL
BTK Inhibition in CLL: Real-World Data
Combination Therapies With BTK Targeted Therapy in CLL
Long-Term Experience With BTK Inhibitors for CLL
BTK Inhibitors for Elderly Patients With CLL
MRD and 11q Deletions in CLL
Selecting Frontline Therapy for CLL
Acalabrutinib Treatment Considerations in CLL
Acalabrutinib Versus Ibrutinib for CLL
BTK-Targeted Therapy for CLL
Expanding Options for Treatment of CLL Using BTK Inhibitors
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Future Directions for R/R DLBCL
L-MIND Study: R/R DLBCL
Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies
CAR T: CD19-Targeted Therapy in R/R DLBCL
Newly Diagnosed Relapsed/Refractory DLBCL
The Future of DLBCL Management
CD19 and CD20 Antibodies in Development
Re-MIND Versus L-MIND Regimen
L-MIND Combination Therapy Dosing Schedule
Transplant Ineligibility: Anti-CD19 Combination Therapy